TTY Biopharm Company Limited (TPEX:4105)
75.40
+0.90 (1.21%)
May 8, 2026, 1:30 PM CST
TTY Biopharm Company Revenue
TTY Biopharm Company had revenue of 1.52B TWD in the quarter ending March 31, 2026, with 4.23% growth. This brings the company's revenue in the last twelve months to 6.51B, up 7.16% year-over-year. In the year 2025, TTY Biopharm Company had annual revenue of 6.45B with 9.49% growth.
Revenue (ttm)
6.51B
Revenue Growth
+7.16%
P/S Ratio
2.88
Revenue / Employee
19.05M
Employees
342
Market Cap
18.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.45B | 559.10M | 9.49% |
| Dec 31, 2024 | 5.89B | 388.31M | 7.05% |
| Dec 31, 2023 | 5.51B | 443.94M | 8.77% |
| Dec 31, 2022 | 5.06B | 526.00M | 11.60% |
| Dec 31, 2021 | 4.54B | 313.77M | 7.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals | 19.01B |
| Grape King Bio | 10.25B |
| YungShin Global Holding | 8.38B |
| Standard Chemical & Pharmaceutical | 7.02B |
| Synmosa Biopharma | 6.19B |
| Formosa Laboratories | 4.85B |
| ScinoPharm Taiwan | 3.14B |
| Handa Pharmaceuticals | 1.73B |